1. Home
  2. PRCH vs DCTH Comparison

PRCH vs DCTH Comparison

Compare PRCH & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PRCH

Porch Group Inc.

HOLD

Current Price

$7.38

Market Cap

753.7M

Sector

Technology

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$9.67

Market Cap

311.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRCH
DCTH
Founded
2012
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
753.7M
311.7M
IPO Year
2019
2015

Fundamental Metrics

Financial Performance
Metric
PRCH
DCTH
Price
$7.38
$9.67
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
4
Target Price
$18.00
$22.00
AVG Volume (30 Days)
991.6K
292.8K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
90.91
107.53
EPS
N/A
0.07
Revenue
$482,414,000.00
N/A
Revenue This Year
$3.89
$24.54
Revenue Next Year
$16.80
$33.15
P/E Ratio
N/A
$138.57
Revenue Growth
10.18
N/A
52 Week Low
$4.65
$8.12
52 Week High
$19.44
$18.23

Technical Indicators

Market Signals
Indicator
PRCH
DCTH
Relative Strength Index (RSI) 47.34 55.06
Support Level $6.54 $8.72
Resistance Level $8.29 $10.17
Average True Range (ATR) 0.42 0.30
MACD 0.03 0.07
Stochastic Oscillator 61.54 77.27

Price Performance

Historical Comparison
PRCH
DCTH

About PRCH Porch Group Inc.

Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has four reportable segments: Insurance Services, Software & Data, Consumer Services, and Corporate. The majority of revenue is from the Insurance segment. The Insurance Services segment manages and operates the Reciprocal, providing services related, but not limited, to underwriting, policy renewal, risk management, insurance portfolio management, financial management, and setting investment guidelines in exchange for commissions and fees.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: